DK3220952T3 - Fremgangsmåde til behandling eller forebyggelse af slagtilfælde - Google Patents

Fremgangsmåde til behandling eller forebyggelse af slagtilfælde Download PDF

Info

Publication number
DK3220952T3
DK3220952T3 DK15861231.7T DK15861231T DK3220952T3 DK 3220952 T3 DK3220952 T3 DK 3220952T3 DK 15861231 T DK15861231 T DK 15861231T DK 3220952 T3 DK3220952 T3 DK 3220952T3
Authority
DK
Denmark
Prior art keywords
battles
prevention
procedure
treatment
Prior art date
Application number
DK15861231.7T
Other languages
Danish (da)
English (en)
Inventor
Ulf Eriksson
Ingrid Nilsson
Daniel Lawrence
Enming Joe Su
Original Assignee
Csl Ltd
B Creative Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014904606A external-priority patent/AU2014904606A0/en
Application filed by Csl Ltd, B Creative Sweden Ab filed Critical Csl Ltd
Application granted granted Critical
Publication of DK3220952T3 publication Critical patent/DK3220952T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24029—Aureolysin (3.4.24.29)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
DK15861231.7T 2014-11-17 2015-11-17 Fremgangsmåde til behandling eller forebyggelse af slagtilfælde DK3220952T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014904606A AU2014904606A0 (en) 2014-11-17 Method of treating or preventing stroke
PCT/AU2015/050720 WO2016077878A1 (en) 2014-11-17 2015-11-17 Method of treating or preventing stroke

Publications (1)

Publication Number Publication Date
DK3220952T3 true DK3220952T3 (da) 2021-07-19

Family

ID=56012959

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15861231.7T DK3220952T3 (da) 2014-11-17 2015-11-17 Fremgangsmåde til behandling eller forebyggelse af slagtilfælde

Country Status (12)

Country Link
US (2) US10336821B2 (enExample)
EP (1) EP3220952B1 (enExample)
JP (1) JP6863892B2 (enExample)
KR (1) KR102560025B1 (enExample)
CN (1) CN107106681B (enExample)
AU (1) AU2015349610B2 (enExample)
CA (1) CA2967070C (enExample)
DK (1) DK3220952T3 (enExample)
ES (1) ES2881303T3 (enExample)
PL (1) PL3220952T3 (enExample)
RU (1) RU2744909C2 (enExample)
WO (1) WO2016077878A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2838246C (en) 2011-06-13 2018-07-10 Csl Limited Antibodies against g-csfr and uses thereof
US10617756B2 (en) * 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia
WO2019055589A1 (en) * 2017-09-13 2019-03-21 The Regents Of The University Of Michigan INHIBITION OF PROTEIN KINASE C TO EXTEND THE TREATMENT OF THE TISSUE ACTIVATOR OF PLASMINOGEN FOR ISCHEMIC DISEASE
PL3717011T3 (pl) 2017-11-29 2023-03-27 Csl Limited Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu
WO2019178645A1 (en) 2018-03-23 2019-09-26 Csl Limited Method of treating asthma
WO2025007195A1 (en) 2023-07-05 2025-01-09 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232439A1 (en) 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
AU2005269265B2 (en) * 2004-08-02 2012-01-12 Zenyth Operations Pty Ltd A method of treating cancer comprising a VEGF-B antagonist
TWI323734B (en) * 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
EP2548579B1 (en) 2006-05-17 2015-09-02 The Ludwig Institute for Cancer Research Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
WO2009036149A2 (en) * 2007-09-15 2009-03-19 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Methods for treatment of degenerative disease associated with apoptosis
AU2009233718A1 (en) * 2008-04-09 2009-10-15 Ludwig Institute For Cancer Research Regulation of fatty acid transporters
JP5823671B2 (ja) * 2009-07-27 2015-11-25 国立大学法人 新潟大学 免疫製剤を含む脳梗塞治療用医薬品組成物
DK3074038T3 (en) 2013-11-28 2019-03-11 Csl Ltd METHOD OF TREATING DIABETIC NEPHROPATHY
JP6553618B2 (ja) 2013-12-18 2019-07-31 シーエスエル リミティド 創傷を治療する方法

Also Published As

Publication number Publication date
US10961304B2 (en) 2021-03-30
KR102560025B1 (ko) 2023-07-26
WO2016077878A1 (en) 2016-05-26
ES2881303T3 (es) 2021-11-29
EP3220952A1 (en) 2017-09-27
AU2015349610A1 (en) 2017-05-25
CA2967070C (en) 2024-03-12
BR112017010336A2 (pt) 2018-05-15
RU2744909C2 (ru) 2021-03-17
RU2017120031A (ru) 2018-12-19
KR20170082631A (ko) 2017-07-14
EP3220952A4 (en) 2018-03-28
US20190315849A1 (en) 2019-10-17
US20180237513A1 (en) 2018-08-23
AU2015349610B2 (en) 2021-08-26
JP2017535551A (ja) 2017-11-30
CN107106681B (zh) 2021-11-09
US10336821B2 (en) 2019-07-02
EP3220952B1 (en) 2021-04-21
JP6863892B2 (ja) 2021-04-21
PL3220952T3 (pl) 2022-01-31
CA2967070A1 (en) 2016-05-26
CN107106681A (zh) 2017-08-29
RU2017120031A3 (enExample) 2019-05-15

Similar Documents

Publication Publication Date Title
GB2558826B (en) Mitigation of anti-sandbox malware techniques
DK3285803T3 (da) Fremgangsmåder til behandling eller forebyggelse af migrænehovedpine
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3718507T3 (da) Anordninger til behandling af nedre ekstremitetsvaskulatur
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3261726T3 (da) Sammensætning til behandling af acne
IL255185A0 (en) 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto
DK3134084T3 (da) Fremgangsmåde til behandling af lungeadenokarcinom
BR112016022976A2 (pt) Métodos para o tratamento de hcv
DK3233071T3 (da) Fremgangsmåde til behandling eller forebyggelse af Ras-medierede sygdomme
DK3395360T3 (da) Plasminogen til forebyggelse eller behandling af diabetisk retinopati
DK3283210T3 (da) Fremgangsmåde
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
PL3393468T3 (pl) Metody leczenia niedoboru odporności